Recent news on Ranolazine

CV Therapeutics Cuts Costs  -  25 May 2007
The Street,Shares of CV fell 32% in a single day back in March after the company said the Merlin Timi-36 study of its ranolazine drug didn't meet its primary efficacy

Ranolazine safe but not effective in reducing major cardiac events ...  -  Apr 26, 2007
News-Medical.net,The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as

Ranolazine does not reduce cardiovascular risks; study  -  Apr 25, 2007
Earthtimes.orgStating that the anti-anginal medication ranolazine has shown some promise in the treatment of acute coronary syndromes (ACS), a team of scientists

New anti-anginal ready for primetime  -  May 11, 2007
National Review of Medicine,Ranolazine, the first entrant from the first genuinely new class of anti-anginal drugs to be introduced in 25 years, doesn't lead to arrythmias as many

Anti-anginal Drug Safe But Not Effective In Reducing Major Cardiac ...  -  Apr 25, 2007
Science Daily (press release)Science Daily — The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major

CV Therapeutics Announces Five Abstracts Accepted for Presentation ...  -  May 3, 2007
PR Newswire (press release),Ranolazine and Propafenone Both Suppress Atrial Fibrillation but Ranolazine unlike Propafenone Does it Without Prominent Effects on Ventricular Myocardium.

CV Therapeutics Submits New Drug Application For Regadenoson  -  May 15, 2007
PipelineReview.com (press release),CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not

New data supports safety of ranolazine but not its effectiveness  -  26 Apr 2007
News-Medical.net,The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as

Drug Works for Chest Pain but Doesn't Save Lives  -  Apr 24, 2007
Ivanhoe,Researchers from Brigham and Women's Hospital in Boston compared patients treated with ranolazine (Ranexa) after coming to the hospital with sudden chest

Angina drug's heart benefit doubted  -  Apr 24, 2007
United Press InternationalBOSTON April 24 (UPI) -- The anti-angina drug ranolazine is safe but does not change outcomes in patients with acute coronary syndrome,

This Week in JAMA  -  Apr 24, 2007
Journal of American Medical Association (subscription),Ranolazine, a novel antianginal agent, is approved for patients with chronic angina, but whether it might benefit patients with acute coronary syndromes

JACC Publishes Long-Term Safety and Tolerability Data from ...  -  Apr 6, 2007
Drug Newswire (press release),..."The high rate of patients choosing to continue on ranolazine in the ROLE program suggests they were perceiving a benefit from ranolazine.

MERLIN: No role for ranolazine in ACS but first-line indication in ...  -  Mar 27, 2007
TheHeart.Org,New Orleans, LA - The new antianginal drug ranolazine (CV Therapeutics) has no role in ACS patients, according to the results of the MERLIN TIMI-36 trial.

CV Therapeutics Reports 2007 First Quarter Financial Results  -  Apr 24, 2007
PR Newswire (press release),For the quarter ended March 31, 2007, the Company recorded $12.0 million of net product sales for sales of Ranexa(R) (ranolazine extended-release tablets),

CV Therapeutics to Announce 2007 First Quarter Financial Results ...  -  Apr 18, 2007
Earthtimes.orgCV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have

CV Therapeutics Shares Reverse Course on Positive American College ...  -  Mar 27, 2007
Seeking Alpha,The company announced that though the MERLIN TIMI-36 study ranolazine (Ranexa) did not produce a statistically significant reduction in the composite

Coronary sinus reducer enhances blood flow in ischemic parts of ...  -  Apr 24, 2007
TheHeart.Org,..."Now we have a new kid on the block, ranolazine, and that's made some people feel pretty good who have so-called refractory angina," Conti said.

Medical News from the Business Pages  -  Apr 7, 2007
CounterPunch,Similarly, "Researchers said the angina drug ranolazine, marketed as Ranexa by CV Therapeutics, Inc., didn't show a benefit in reducing deaths and heart

JACC Publishes Long-Term Safety And Tolerability Data From ...  -  Mar 15, 2007
Medical News Today (press release),CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the Journal of the American College of Cardiology (JACC) has published data from the Ranolazine

JACC Publishes Long-Term Safety and Tolerability Data from ...  -  Mar 14, 2007
PR Newswire (press release),..."The high rate of patients choosing to continue on ranolazine in the ROLE program suggests they were perceiving a benefit from ranolazine.

MERLIN TIMI-36: Ranolazine fails for ACS, but safety record may ...  -  Mar 7, 2007
TheHeart.Org,The study, sponsored by CV Therapeutics, compared long-term treatment with extended-release ranolazine with placebo, on top of standard therapy,

Regulator warns users of legal drug  -  Mar 23, 2007
TUV Product Service,...which is the active component in BZP, are also used in pharmaceutical products such as impotence drug Viagra and anti-angina medicine Ranolazine.

CV Therapeutics Announces Topline MERLIN TIMI-36 Results  -  Mar 7, 2007
Medical News Today (press release),CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ranolazine shows there was no

CV Therapeutics Announces Topline MERLIN TIMI-36 Results  -  Mar 6, 2007
PR Newswire (press release),Study Design MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is a multi-national,

CV Therapeutics Announces Topline MERLIN TIMI-36 Results  -  Mar 6, 2007
Earthtimes.orgPALO ALTO, Calif., March 6 -- CV Therapeutics, Inc. announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ranolazine shows

Market Report -- In Play (CVTX)  -  Mar 14, 2007
MSN MoneyCV Therapeutics says JACC publishes long-term safety and tolerability data from Ranolazine open label experience program Co announces that the Journal of

CV Therapeutics Study Misses Endpoint  -  Mar 6, 2007
TheStreet.comCV Therapeutics (CVTX - Cramer's Take - Stockpickr) said the Merlin Timi-36 study of its ranolazine drug didn't meet its primary efficacy endpoint.

Stocks To Watch: Chico's FAS, Heelys, Hewlett-Packard, TXU ...  -  Mar 7, 2007
Minyanville.com,CV Therapeutics (CVTX) said ranolazine didn't meet the primary efficacy endpoint in a clinical trial. The biopharmaceutical company also said data from its

Market Report -- In Play (CVTX)  -  Mar 6, 2007
MSN Money...of unblinded data from the MERLIN TIMI-36 study of ranolazine shows there was no adverse trend in death or arrhythmias in patients on ranolazine.

Google Rises, but Stocks Stay Flat  -  Mar 7, 2007
Wall Street Journal (subscription),CV Therapeutics sank 2.80, or 22.8%, to 9.50 after the company said its drug to treat chronic chest pain, ranolazine, didn't meet the primary efficacy

CV Therapeutics sinks; Payless up 7% after results  -  Mar 7, 2007
MarketWatch...tumbled 27% to close the session at $8.93 a share after the biotech firm said that cardiac treatment ranolazine didn't meet the primary efficacy endpoint in

AFTER HOURS CV Therapeutics sinks; Payless up 6% after results  -  Mar 6, 2007
MarketWatch...tumbled 28% to trade at $8.91 a share after the biotech firm said that cardiac treatment ranolazine didn't meet the primary efficacy endpoint in a clinical

CV Therapeutics Angina Drug Not Effective in Study; Shares Plunge  -  Mar 7, 2007
CNBC,...[CVTX 9.30 -3.00 (-24.39%) ] following the company's announcement late Tuesday that its angina drug ranolazine was not effective in a study of acute and

UPDATE 1-CV angina drug not effective in ACS study  -  Mar 6, 2007
ReutersWhile ineffective for ACS, there was no adverse trend in death or arrhythmias in patients taking the drug, also known by the chemical name ranolazine,

CV Therapeutics Drug Fails Study  -  Mar 6, 2007
Forbes,Biopharmaceutical company CV Therapeutics Inc. said Tuesday its angina drug ranolazine, or Ranexa, showed no adverse trend in deaths or arrhythmias,

CV Therapeutics angina drug not effective in study  -  Mar 6, 2007
ReutersThere was no adverse trend in death or arrhythmias in patients taking the drug, also known by the chemical name ranolazine, the company said.

CV Therapeutics Shares Fall As Angina Drug Fails To Meet Target ...  -  Mar 7, 2007
Trading Markets,...(RTTNews) - Tuesday after the bell, CV Therapeutics, Inc. (CVTX | charts | news | PowerRating) said data from a clinical trial of ranolazine showed the drug

CV Therapeutics Is Losing Ground On Study Results  -  Mar 6, 2007
Trading Markets,...(RTTNews) - CV Therapeutics (CVTX | charts | news | PowerRating) announced after the bell Tuesday that results from its MERLIN TIMI-36 study of ranolazine

CV Therapeutics drug fails study  -  Mar 6, 2007
Hemscott,...(AP) - Biopharmaceutical company CV Therapeutics Inc. said Tuesday its angina drug ranolazine, or Ranexa, showed no adverse trend in deaths or arrhythmias,

Stocks to Watch, March 7: American Eagle Outfitters, TIVO, Chico's FAS  -  Mar 6, 2007
FOX NewsThe Palo Alto, Calif., biopharmaceutical company also said data from its ranolazine study indicates no adverse trend in death or arrhythmias in patients on

What's going to be hot at ACC 2007?  -  Mar 19, 2007
TheHeart.Org,As reported by heartwire, CV Therapeutics announced March 7, 2007 that its MERLIN TIMI-36 trial of ranolazine had failed to reach its primary end point.

Pre-Market Stock Notes (MAR 14, 2007)  -  Mar 14, 2007
24/7 Wall St.,...(CVTX) CV Therapeutics says JACC publishes long-term safety and tolerability data from Ranolazine open label experience program.

Ranexa Won't Treat Heart Attacks, CV Therapeutics Falls 24%  -  Mar 8, 2007
Seeking Alpha,While CV Therapeutics' Ranexa or Ranolazine trials proved that there is no greater risk of arrhythmia or abnormal heart beats, it didn't prove Ranexa's

Biotech Day in Review: Avalon Signs $200 Million Deal with Merck  -  Mar 8, 2007
Seeking Alpha,CV Therapeutics (CVTX) reported that Ranexa (ranolazine) failed a Phase III trial in patients with acute coronary syndrome. The drug was given to patients

CV Therapeutics shares take a tumble on study results  -  Mar 8, 2007
Pharma Times (subscription),...in the 6500-patient study, which was designed to evaluate the efficacy and safety of Ranexa (ranolazine) during acute and long-term treatment.

Stocks Close Lower After A Choppy Trading Session - US Commentary  -  Mar 7, 2007
Trading Markets,...closing down 23.6 after the biopharmaceutical company said its angina drug ranolazine did not meet the primary efficacy endpoint in a late stage study.

Aftermarket Movers: Chico's, Payless  -  Mar 6, 2007
Forbes,...to $9.10 in the after hours session, after the biotech said its angina drug ranolazine, or Ranexa, failed to meet its goal in a late stage study.

Scania Helps European Rise  -  Mar 7, 2007
123Jump.com,Drug company CV Therapeutics Inc. (CVTX: chart) weighed heavily on the Nasdaq with a decline of 25% as its angina drug ranolazine did not meet the primary

Stocks Turning In A Lackluster Performance In Morning Trading - US ...  -  Mar 7, 2007
Trading Markets,...with the biopharmaceutical company currently down 26.1 percent after its angina drug ranolazine did not meet the primary efficacy endpoint in a late

MERLIN TIMI-36 Study Accepted As Late Breaking Clinical Trial at ...  -  Feb 7, 2007
PR Newswire (press release),The MERLIN TIMI-36 study (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is scheduled for presentation

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace ...  -  Feb 21, 2007
PR Newswire (press release),CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have

CV Therapeutics Reports 2006 Fourth Quarter and Full Year ...  -  Feb 9, 2007
PharmaLive.com (press release),For the quarter ended December 31, 2006, the Company recorded $9.0 million of net product sales for sales of Ranexa(R) (ranolazine extended-release tablets)

Will MERLIN Work Magic For CV Therapeutics?  -  Feb 6, 2007
Seeking Alpha,...“It has conducted the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes, or MERLIN TIMI-36, clinical study

CV Therapeutics to Announce 2006 Fourth Quarter and Year End ...  -  Jan 17, 2007
Earthtimes.orgCV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not

CV Therapeutics Files Application for European Marketing Approval ...  -  Dec 21, 2006
PipelineReview.com (press release),...announced today that a Marketing Authorization Application (MAA) seeking approval of ranolazine for the treatment of chronic angina has been filed with the

CV Therapeutics Files Application for European Marketing Approval ...  -  Dec 21, 2006
PharmaLive.com (press release),The MAA for ranolazine, a new chemical entity, has been filed for review under the EMEA centralized procedure by the company's European subsidiary,

CV Therapeutics Files Application for European Marketing Approval ...  -  Dec 20, 2006
Earthtimes.org20 -- CV Therapeutics, Inc. announced today that a Marketing Authorization Application (MAA) seeking approval of ranolazine for the treatment of chronic

CV Therapeutics Files for Ranolazine OK  -  Dec 20, 2006
Houston Chronicle,Drug developer CV Therapeutics Inc. said Wednesday it asked European regulators to approve its chronic angina treatment ranolazine.

Market Report -- In Play (CVTX)  -  Dec 20, 2006
MSN MoneyCV Therapeutics files application for european marketing approval of Ranolazine for treatment of chronic angina Co announces a Marketing Authorization

CV Therapeutics seeks Europe's OK of angina drug  -  Dec 22, 2006
San Jose Business Journal,Palo Alto-based CV Therapeutics said ranolazine -- which is already on the market in the US -- has been filed for review with the European Medicines Agency.

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace ...  -  Jan 4, 2007
PharmaLive.com (press release),CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not

MedImmune, CSL Enter Licensing Deal and CV Therapeutics Files ...  -  Dec 21, 2006
Financial News USA (press release),CV Therapeutics, Inc. (Nasdaq: CVTX) recently announced that a Marketing Authorization Application (MAA) seeking approval of ranolazine for the treatment of

(PRN) - Synergx Systems Inc. Announces New Transit Contract ... [+]  -  Dec 20, 2006
Bolsamania.com,...(PRN) - CV Therapeutics Files Application for European Marketing Approval of Ranolazine for Treatment of Chronic Angina ... [+]

CV Therapeutics Seeks Europe's OK of Angina Drug and Genzyme Seeks ...  -  26 Dec 2006
Financial News USA (press release),Palo Alto-based CV Therapeutics said ranolazine -- which is already on the market in the US -- has been filed for review with the European Medicines Agency.

CV Therapeutics Files Application for European Marketing Approval ...  -  Dec 21, 2006
PipelineReview.com (press release),...announced today that a Marketing Authorization Application (MAA) seeking approval of ranolazine for the treatment of chronic angina has been filed with the

CV Therapeutics Files Application for European Marketing Approval ...  -  Dec 21, 2006
PharmaLive.com (press release),The MAA for ranolazine, a new chemical entity, has been filed for review under the EMEA centralized procedure by the company's European subsidiary,

CV Therapeutics Files Application for European Marketing Approval ...  -  Dec 20, 2006
Earthtimes.org20 -- CV Therapeutics, Inc. announced today that a Marketing Authorization Application (MAA) seeking approval of ranolazine for the treatment of chronic

CV Therapeutics Files for Ranolazine OK  -  Dec 20, 2006
Houston Chronicle,Drug developer CV Therapeutics Inc. said Wednesday it asked European regulators to approve its chronic angina treatment ranolazine.

Market Report -- In Play (CVTX)  -  Dec 20, 2006
MSN MoneyCV Therapeutics files application for european marketing approval of Ranolazine for treatment of chronic angina Co announces a Marketing Authorization

CV Therapeutics seeks Europe's OK of angina drug  -  Dec 22, 2006
San Jose Business Journal,Palo Alto-based CV Therapeutics said ranolazine -- which is already on the market in the US -- has been filed for review with the European Medicines Agency.

MedImmune, CSL Enter Licensing Deal and CV Therapeutics Files ...  -  Dec 21, 2006
Financial News USA (press release),CV Therapeutics, Inc. (Nasdaq: CVTX) recently announced that a Marketing Authorization Application (MAA) seeking approval of ranolazine for the treatment of

(PRN) - Synergx Systems Inc. Announces New Transit Contract ... [+]  -  Dec 20, 2006
Bolsamania.com,...(PRN) - CV Therapeutics Files Application for European Marketing Approval of Ranolazine for Treatment of Chronic Angina ... [+]

Regadenoson Meets Primary Endpoint in Second Phaase 3 Clinical Trial  -  Dec 5, 2006
PipelineReview.com (press release),CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not

Good vibrations  -  Nov 30, 2006
Connecticut Post,For those people, he recommends other treatments, such as the medication ranolazine, which also treats chronic refractory angina.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional